The evidence for Cannabidiol is building
Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to a placebo. While the cost-effectiveness estimates are uncertain, the benefits of reducing the severity of seizures and lowering the risk of sudden unexpected death in epilepsy make it an appropriate use of NHS resources. Therefore, it is recommended as a treatment option by NICE.
Recent Posts
Transforming Brain Health Innovation with Patient Experience Data: Strategic Insights for Health ...
Innovative approaches to brain health increasingly recognize that patient experience data (PXD)—systematically collected information on patients’ lived experiences of interventions and disease—are crucial for aligning research, development, and regulatory decisions with real-world needs. The refe...
Comprehensive Review of Type 2 Diabetes Treatment and Diagnosis Strategies
Type 2 diabetes treatment is a complex and evolving topic, with patients and clinicians often asking: “What are the most effective and current strategies for managing adult type 2 diabetes?” In recent years, traditional medical sources highlight the importance of individualized care—blending life...
Dutch Pharmacoeconomic Redesign: Streamlined Structure and Enhanced Transparency for Drug Assessment
The recently published concept report from the Dutch National Health Care Institute (Zorginstituut Nederland) introduces a fundamentally new structure for pharmacoeconomic assessments, known as the Dutch Pharmacoeconomic Redesign, effective September 1, 2025. This revised format applies to both d...